Clozapine:norclozapine ratio as a marker of metabolic risk and therapeutic response and effect of valproate on clozapine levels

AIMS: Clozapine is the most effective antipsychotic in treatment-resistant schizophrenia. Clozapine causes weight gain and increased diabetes risk. The role of its metabolite norclozapine and clozapine:norclozapine ratio (CLZ/NCLZ) in metabolic effects has been debated. Also, the role of norclozapine in efficacy of clozapine treatment has been an area of interest. Valproate raises CLZ/NCLZ, but its impact on clozapine levels has been unclear. The aims of this study were to (1) examine associations between CLZ/NCLZ and metabolic markers, (2) assess whether concomitant valproate is associated with clozapine and norclozapine serum concentrations and CLZ/NCLZ and (3) evaluate whether CLZ/NCLZ is associated with treatment response, using antipsychotic or mood stabilizer augmentation as a proxy for treatment resistance. METHODS: We studied 237 psychosis patients on clozapine, with weight gain data for 228 patients and serum levels and metabolic markers for 190 patients. The studied outcomes were weight gain, hyperglycaemia or diabetes and dyslipidaemia. Effects of clozapine concentration/dose (C/D), norclozapine C/D and CLZ/NCLZ on outcomes were analysed, adjusting for age, sex and smoking. CLZ/NCLZ was compared between augmented and clozapine-only patients to assess treatment response. RESULTS: Lower CLZ/NCLZ ratios did not predict weight gain, hyperglycaemia or dyslipidaemia. CLZ/NCLZ was not associated with polypharmacy. Valproate showed a non-significant increase of clozapine C/D by 21.8% (95% confidence interval [CI] -0.3% to 49.0%, p = .054) and a significant increase in CLZ/NCLZ by 76.1% (95% CI +58.8% to +95.2%, p < .001). CONCLUSIONS: CLZ/NCLZ is not linked to metabolic outcomes or treatment response in our study. Valproate elevated CLZ/NCLZ significantly. We observed higher clozapine serum levels among patients receiving valproate, but the association was not statistically significant.

Authors

Institutions

Publication Details

Journal
British Journal of Clinical Pharmacology
Published
2026-07-26
DOI
https://doi.org/10.1002/bcp.70706
Primary Topic
Schizophrenia research and treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clozapine:norclozapine ratio as a marker of metabolic risk and therapeutic response and effect of valproate on clozapine levels

Eeva Moilanen, Mari Hämäläinen, Anssi Solismaa, Susanna Maria Rask et al.
British Journal of Clinical Pharmacology
Schizophrenia research and treatment
article

Clozapine:norclozapine ratio as a marker of metabolic risk and therapeutic response and effect of valproate on clozapine levels

Eeva Moilanen, Mari Hämäläinen, Anssi Solismaa, Susanna Maria Rask, Olli Kampman, Miina Lamminmäki, Niko Seppälä
article en

Abstract

AIMS: Clozapine is the most effective antipsychotic in treatment-resistant schizophrenia. Clozapine causes weight gain and increased diabetes risk. The role of its metabolite norclozapine and clozapine:norclozapine ratio (CLZ/NCLZ) in metabolic effects has been debated. Also, the role of norclozapine in efficacy of clozapine treatment has been an area of interest. Valproate raises CLZ/NCLZ, but its impact on clozapine levels has been unclear. The aims of this study were to (1) examine associations between CLZ/NCLZ and metabolic markers, (2) assess whether concomitant valproate is associated with clozapine and norclozapine serum concentrations and CLZ/NCLZ and (3) evaluate whether CLZ/NCLZ is associated with treatment response, using antipsychotic or mood stabilizer augmentation as a proxy for treatment resistance. METHODS: We studied 237 psychosis patients on clozapine, with weight gain data for 228 patients and serum levels and metabolic markers for 190 patients. The studied outcomes were weight gain, hyperglycaemia or diabetes and dyslipidaemia. Effects of clozapine concentration/dose (C/D), norclozapine C/D and CLZ/NCLZ on outcomes were analysed, adjusting for age, sex and smoking. CLZ/NCLZ was compared between augmented and clozapine-only patients to assess treatment response. RESULTS: Lower CLZ/NCLZ ratios did not predict weight gain, hyperglycaemia or dyslipidaemia. CLZ/NCLZ was not associated with polypharmacy. Valproate showed a non-significant increase of clozapine C/D by 21.8% (95% confidence interval [CI] -0.3% to 49.0%, p = .054) and a significant increase in CLZ/NCLZ by 76.1% (95% CI +58.8% to +95.2%, p < .001). CONCLUSIONS: CLZ/NCLZ is not linked to metabolic outcomes or treatment response in our study. Valproate elevated CLZ/NCLZ significantly. We observed higher clozapine serum levels among patients receiving valproate, but the association was not statistically significant.

British Journal of Clinical Pharmacology
University Consortium of Pori (FI), Tampere University of Applied Sciences (FI), University of Turku (FI), Satakunta University of Applied Sciences (FI), Turku University Hospital (FI), Vanha Vaasa hospital (FI), Pirkanmaa Hospital District (FI), Tampere University Hospital (FI), Tampere University (FI), Umeå University (SE)
Tampereen Yliopisto
Good health and well-being
Openalex Percentile: Top 8%
Schizophrenia research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.